INZY Stock Overview
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Inozyme Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.74 |
| 52 Week High | US$7.80 |
| 52 Week Low | US$2.69 |
| Beta | 1.37 |
| 1 Month Change | -26.05% |
| 3 Month Change | -10.23% |
| 1 Year Change | -19.52% |
| 3 Year Change | -70.63% |
| 5 Year Change | n/a |
| Change since IPO | -72.98% |
Recent News & Updates
Recent updates
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Apr 11
Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
Mar 08Inozyme Pharma GAAP EPS of -$0.38
Aug 15Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency
Jul 19Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?
Jul 12We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation
Dec 22Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth
Sep 08We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
May 22Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency
May 07We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely
Feb 06
Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder
Jan 04Inozyme Pharma (INZY) Investor Presentation - Slideshow
Dec 03Inozyme Pharma EPS misses by $1.02
Nov 12Shareholder Returns
| INZY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.8% | 4.8% | 0.7% |
| 1Y | -19.5% | 2.8% | 23.9% |
Return vs Industry: INZY underperformed the US Biotechs industry which returned 2.7% over the past year.
Return vs Market: INZY underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| INZY volatility | |
|---|---|
| INZY Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INZY's share price has been volatile over the past 3 months.
Volatility Over Time: INZY's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 59 | Doug Treco | www.inozyme.com |
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company’s lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products.
Inozyme Pharma, Inc. Fundamentals Summary
| INZY fundamental statistics | |
|---|---|
| Market cap | US$293.20m |
| Earnings (TTM) | -US$71.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.1x
P/E RatioIs INZY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INZY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$71.17m |
| Earnings | -US$71.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 31.9% |
How did INZY perform over the long term?
See historical performance and comparison